PRECIGEN, INC. Interest Expense Nonoperating
PRECIGEN, INC. (PGEN) reported Interest Expense Nonoperating of $2.95 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement
us-gaap:InterestExpenseNonoperating · last filed 2026-08-04
- PRECIGEN, INC. interest expense nonoperating for the quarter ending 2026-06-30 was $2.95M.
- PRECIGEN, INC. interest expense nonoperating for the quarter ending 2026-03-31 was $2.91M, a 290700.00% increase year-over-year.
- PRECIGEN, INC. interest expense nonoperating for the quarter ending 2025-06-30 was $0.00.
- PRECIGEN, INC. interest expense nonoperating for the quarter ending 2025-03-31 was $1.00K.
- PRECIGEN, INC. interest expense nonoperating for fiscal 2025 was $3.87M, a 64350.00% increase from fiscal 2024.
- PRECIGEN, INC. interest expense nonoperating for fiscal 2024 was $6.00K, a 98.72% decline from fiscal 2023.
- PRECIGEN, INC. interest expense nonoperating for fiscal 2023 was $468.00K.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|
| 2026-06-30 | $2.95M 10-Q · filed 2026-08-04 | $5.86M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $2.91M 10-Q · filed 2026-05-13 | ||
| 2025-12-31 | $3.87M 10-K · filed 2026-03-25 | ||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-04 | $1.00K 10-Q · filed 2026-08-04 | |
| 2025-03-31 | $1.00K 10-Q · filed 2026-05-13 | ||
| 2024-12-31 | $6.00K 10-K · filed 2026-03-25 | ||
| 2023-12-31 | $468.00K 10-K · filed 2026-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |